High Tide's German Subsidiary Remexian Pharma Showcases Exclusive Canadian Medical Cannabis Brand Partnerships at Mary Jane Berlin 2026
High Tide Reports Second Quarter 2026 Financial Results Featuring Record Revenue of $179.3MM, and Adjusted EBITDA of $13.9MM
High Tide Reports Record Quarterly Distribution of 7.6 Tonnes of Medical Cannabis Through Remexian Pharma GmbH, Accelerating German Market Leadership
High Tide Executes a Term Sheet for $40MM of Credit Facilities with a Big 5 Canadian Chartered Bank As its New Senior Lender
Metalsource Mining Extends Strike Length of Mineralization at Silver Hill with 65m South Step Out from SH26-19
Bold Ventures Identifies Widespread Rare Earth Element Anomalies at Burchell, Plans Next Phase of Exploration
Purecore Signs Definitive Agreement with Skyharbour for Yurchison Uranium Property Option in Athabasca Basin
